Stock of the Day

September 9, 2021

Zai Lab (ZLAB)

$25.46
-$0.62 (-2.4%)
Market Cap: $2.97B

About Zai Lab

Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience. Its commercial products include Zejula, an orally administered poly polymerase 1/2 inhibitor; Optune, a cancer therapy that uses electric fields tuned to specific frequencies to kill tumor cells; NUZYRA for acute bacterial skin and skin structure infections, and community acquired bacterial pneumonia; Qinlock to treat gastrointestinal stromal tumors, and VYVGART, a human IgG1 antibody fragment for myesthenia gravis. The company also develops Tumor Treating Fields, a portable device for delivery of electric fields; Repotrectinib, a tyrosine kinase inhibitor (TKI) to target ROS1 and TRK A/B/C in TKI-naïve- or -pretreated cancer patients; Tisotumab vedotin, an antibody drug conjugate; Adagrasib for treating KRAS-G12C-mutated NSCLC, colorectal cancer, and pancreatic cancer; and Bemarituzumab to treat gastric and gastroesophageal junction cancer patients. In addition, it develops Sulbactam/durlobactam, a combination of a beta-lactam antibiotic and a beta-lactamase inhibitor for the treatment of serious infections caused by Acinetobacter; KarXT for the treatment of psychiatric and neurological conditions. It has license and collaboration agreement with Tesaro, Inc. to develop, manufacture, and commercialize niraparib; NovoCure to develop and commercialize Tumor Treating Fields; Deciphera to develop and commercialize ripretinib; Paratek Bermuda Ltd. to develop, manufacture, and commercialize omadacycline; argenx, to develop and commercialize efgartigimod; BMS to develop and commercialize tisotumab vedotin and repotrectinib; Mirati to research, develop, manufacture, and commercialize adagrasib; Amgen to develop and commercialize bemarituzumab; and Innoviva to develop and commercialize Sulbactam-Durlobactam; Karuna to develop and commercialize KarXT. The company was incorporated in 2013 and is headquartered in Shanghai, China.

Today's Trend

Zai Lab Limited (NASDAQ: ZLAB) shares have climbed on strong clinical data and analyst upgrades, although insider stock sales by CEO Ying Du have introduced some caution.

  • Zai Lab announced positive topline Phase 3 FORTITUDE-101 results for bemarituzumab plus chemotherapy, showing a statistically significant overall survival benefit in FGFR2b-positive first-line gastric cancer—a story also picked up by Yahoo Finance and MSN. Business Wire
  • Leerink Partners raised its price target on ZLAB from $73 to $75 and maintained an “outperform” rating, implying more than 100% upside from current levels. MarketBeat
  • Five brokerages covering ZLAB issued a consensus “Moderate Buy” rating, underscoring broad analyst confidence. MarketBeat
  • An analysis noted ZLAB shares gapped up on recent news but questioned if the rally is sustainable, suggesting mixed investor sentiment. MarketBeat
  • CEO Ying Du sold 6,918 shares for $245,727—reducing her stake by 1.3%—in a transaction disclosed June 30. MarketBeat
  • Earlier filings show Ying Du also sold shares valued at approximately $855,161, further trimming insider holdings. American Banking News
← Previous Stock of the DayNext Stock of the Day →

Recent News